NLRP3 and COVID-19: Given that elevated concentrations of IL-1β and IL-6 are associated with adverse clinical outcomes in COVID-19,9, 10 targeting the NLRP3 inflammasome (which is responsible for the maturation and secretion of IL-1β) might reduce related complications in patients at risk of cytokine activation.